ArticleOncology letters2025
Stimulator of interferon genes signaling network-driven prognostic signature for pancreatic cancer: Hub gene discovery with multimodal validation.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The stimulator of interferon genes (STING) signaling pathway plays an important role in tumor progression, particularly in immune regulation. However, the functions of STING-related genes in immunologically 'cold' tumors, such as pancreatic ductal adenocarcinoma (PAAD), are yet to be elucidated. The present study aims to investigate the involvement of STING signaling pathway-associated genes in PAAD progression and immune infiltration. Bioinformatics analysis of PAAD transcriptomic data from public cohorts (TCGA and GEO) revealed that the majority of STING-related genes were highly expressed in PAAD. Based on the expression levels of these genes, patients with PAAD from these cohorts were stratified into high-risk and low-risk groups. These STING-related genes exerted differential impacts on tumor mutational burden, immune infiltration and response to immunotherapy. Utilizing these genes, a prognostic model was constructed (hazard ratio, 2.639; P<0.001) and externally validated. Model analysis indicated that interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) and zinc finger DHHC-type containing 1 (ZDHHC1) may possess notable biological functions in PAAD. Subsequent functional experiments involving knockout of IFIT2 and overexpression of ZDHHC1in PAAD cell lines demonstrated that these genes significantly regulated cell proliferation (assessed by CCK-8 assay) and apoptosis (assessed by TUNEL assay) (P<0.001). In summary, the STING signaling pathway is critically involved in PAAD pathogenesis, and the representative genes IFIT2 and ZDHHC1 exhibit distinct functional roles within this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.